Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

被引：6

作者：

Jaeger, Ulrich

Worel, Nina

McGuirk, Joseph

Riedell, Peter A.

Fleury, Isabelle

Borchmann, Peter

Du, Yan

Abdelhady, Ahmed M.

Han, Xia

Martinez-Prieto, Marcela

Waller, Edmund K.

机构：

[1] Med Univ Vienna, Vienna, Austria

[2] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA

[3] Univ Chicago, Dept Med, Sect Hematol Oncol, 5841 S Maryland Ave, Chicago, IL 60637 USA

[4] Hop Maisonneuve Rosemont, Dept Med Specialisee, Hematooncol, Montreal, PQ, Canada

[5] Klinikum Univ Koln, Cologne, Germany

[6] Novartis Pharma AG, Shanghai, Peoples R China

[7] Novartis Pharmaceut Corp, E Hanover, NJ USA

[8] Emory Clin, Atlanta, GA 30322 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e19537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e19537

引用

页数：3

共 50 条

[31] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
Hess, G.
Thieblemont, C.
Clausen, M. R.
Lugtenburg, P.
Balari, Sureda A.
Zinzani, P. L.
Wu, J.
Finn, L.
Vindelov, S. D.
Fox, C. P.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
[32] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Ayyappan, Sabarish
Kim, Won Seog
Kim, Tae Min
Walewski, Jan
Cho, Seok-Goo
Jarque, Isidro
Iskierka-Jazdzewska, Elzbieta
Poon, Michelle
Oh, Sung Yong
Lim, Francesca Lorraine Wei Inng
Carpio, Cecilia
Tan, Tran-Der
Gutierrez, Antonio
Zhang, Huilai
Cao, Junning
Zhang, Mingzhi
Tessoulin, Benoit
Li, Jingjin
Ufkin, Melanie
Shariff, Saleem
Chi, Lei
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth
Prince, H. Miles
BLOOD, 2023, 142
[33] A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.
Westin, Jason R.
Maris, Michael B.
Al-Katib, Ayad M.
Lakhani, Nehal J.
Patel, Prapti Arvind
Harb, Wael A.
McCaul, Kelly
Patel-Donnelly, Dipti
Messmann, Richard Adam
Klencke, Barbara J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
Sehn, Laurie H.
Herrera, Alex F.
Matasar, Matthew J.
Kamdar, Manali
Assouline, Sarit
Hertzberg, Mark
Kim, Tae Min
Kim, Won-Seog
McMillan, Andrew
Ozcan, Muhit
Hirata, Jamie M.
Penuel, Elicia
Cheng, Ji
Ku, Grace
Flowers, Christopher R.
BLOOD, 2018, 132
[35] A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in CombinationWith Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ribrag, Vincent
Lee, Seung Tae
Rizzieri, David
Dyer, Martin J. S.
Fayad, Luis
Kurzrock, Razelle
Andritsos, Leslie
Bouabdallah, Reda
Hayat, Amjad
Bacon, Larry
Jiang, Yu
Miah, Kowser
Delafont, Bruno
Hamid, Oday
Anyanwu, Stephanie
Martinez, Pablo
Hess, Brian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 309 - +
[36] Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity
Buecklein, Veit
Blumenberg, Viktoria
Ackermann, Josephine
Schmidt, Christian
Rejeski, Kai
Mueller, Niklas
Reischer, Anna
von Baumgarten, Louisa
Schoeberl, Florian
Humpe, Andreas
von Bergwelt, Michael
Subklewe, Marion
BLOOD, 2020, 136
[37] Glofitamab plus Polatuzumab Vedotin demonstrates durable responses and a manageable safety profile in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Dietrich, S.
Hutchings, M.
Avigdor, A.
Sureda, A.
Terol, M. J.
Bosch, F.
Corradini, P.
Larsen, Stauffer T.
Dominguez, Rueda A.
Skarbnik, A.
Jorgensen, J.
Goldschmidt, N.
Gurion, R.
Zinzani, P. L.
Pinto, A.
Cordoba, R.
Bottos, A.
Huang, Z.
Simko, S.
Relf, J.
de L'Etang, Filezac A.
Sellam, G.
Gritti, G.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 209 - 209
[38] Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Awasthi, Rakesh
Tam, Constantine S.
Jaeger, Ulrich
Jaglowski, Samantha
Foley, Stephen Ronan
Van Besien, Koen
Wagner-Johnston, Nina D.
Kersten, Marie Jose
Schuster, Stephen J.
Salles, Gilles Andre
Maziarz, Richard Thomas
Anak, Oezlem
Pacaud, Lida Bubuteishvili
Gazi, Lucien
Waldron, Edward
Hamilton, Jason
Pruteanu, Iulian
Tai, Feng
Mueller, Karen Thudium
Waller, Edmund K.
BLOOD, 2017, 130
[39] Patient-Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)
Maziarz, Richard T.
Bishop, Michael R.
Tam, Constantine S.
Borchmann, Peter
Jaeger, Ulrich
McGuirk, Joseph
Waller, Edmund K.
Jaglowski, Samantha
Andreadis, Charalambos
Foley, Stephen Ronan
Fleury, Isabelle
Mielke, Stephan
Westin, Jason R.
Ho, Phoebe Joy
Bachanova, Veronika
Holte, Harald
Magenau, John M.
Anak, Oezlem
Pacaud, Lida Bubuteishvili
Guenther, Siegbert
Zhang, Jie
Rasouliyan, Lawrence
Tai, Feng
Salles, Gilles A.
Schuster, Stephen J.
BONE MARROW TRANSPLANTATION, 2018, 53 : 177 - 178
[40] Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
Arcari, Annalisa
Chiappella, Annalisa
Valenti, Vanessa
Zanlari, Luca
Tani, Monica
Marasca, Roberto
Cabras, Maria Giuseppina
Spina, Michele
Santagostino, Alberto
Ilariucci, Fiorella
Carli, Giuseppe
Musto, Pellegrino
Savini, Paolo
Marino, Dario
Ghio, Francesco
Gentile, Massimo
Cox, Maria Christina
Della Seta, Roberta
Vallisa, Daniele
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →